Board of Pharmacy public meetings in 2024
4 substantive meetings from 2024, with official agendas or minutes and plain-English summaries.
Board of Pharmacy
The Louisiana Board of Pharmacy will meet to vote on proposed voluntary consent agreements for 13 pharmacies and pharmacists facing disciplinary action, including cases involving Daniel Pharmacy, Walgreens, Walmart, and others. The board will also consider several regulatory proposals, including new rules for pharmacist-in-charge requirements, emergency drug kits, and marijuana pharmacies. Additionally, the board will review the legislative auditor's financial audit report, proposed budget amendments, and a request to allow remote processing by pharmacy technicians.
- Consideration of proposed voluntary consent agreements for 13 disciplinary cases, including Daniel Pharmacy, Walgreens, Walmart, and individual pharmacists
- Regulatory proposals on pharmacist-in-charge requirements, emergency drug kit permits, and marijuana pharmacy rules
- Legislative proposal on prescription monitoring program record retention
- Consideration of legislative auditor's financial audit report for FY 2023-2024 and proposed budgets for FY 2024-2025 and 2025-2026
- Request for approval of New Orleans Career Center pharmacy technician training program
The Board approved the fiscal year 2025-2026 budget and the 2024-2025 budget amendment. It issued several fines to pharmacies for permit violations and controlled substance failures, and updated regulations regarding Pharmacist-in-Charge requirements and medical marijuana authority.
- Approved Proposed Budget for Fiscal Year 2025-2026 (unanimous)
- Approved Proposed Budget Amendment No. 1 for Fiscal Year 2024-2025 (unanimous)
- Fined Wells Pharmacy Network $52,390 and PIC Rhonda Renee Rohr Drobiazgiewicz $5,000 (unanimous)
- Fined Drexi, Inc $41,240 for operating as a PBM without credentials (unanimous)
- Fined Revive Rx, LLC $36,570 and PIC Aaron Michael Schneider $5,000 (unanimous)
- Fined Precision Compounding Pharmacy $25,000 for dispensing without a permit (unanimous)
- Approved Regulatory Proposal 2024-G to remove the two-year experience requirement for PICs (unanimous)
- Approved Regulatory Proposal 2024-I to repeal therapeutic marijuana pharmacy regulations (unanimous)
Board of Pharmacy
The Board of Pharmacy will consider compiled financial statements for Fiscal Year 2023-2024 and review several proposed voluntary consent agreements for pharmacies and individuals. The body will also discuss revisions to the Policy & Procedure Manual regarding facility inspections and the Stepful Pharmacy Technician Training Program.
- Consideration of Fiscal Year 2023-2024 Compiled Financial Statements
- Proposed voluntary consent agreements for Walgreen Pharmacy #110-03047, CVS Pharmacy #5396, and CVS Pharmacy #4743
- Request for approval of Stepful Pharmacy Technician Training Program
- Proposed revisions to Policy & Procedure Manual regarding facility inspections and record retention
- Review of the 2024 Regular Session of the Louisiana Legislature
The Board accepted the compiled financial statements and annual report for Fiscal Year 2023-2024. Members approved several disciplinary consent agreements involving fines and license suspensions, and updated policy manuals regarding sterile compounding and record retention.
- Approved FY 2023-2024 Compiled Financial Statements (unanimous)
- Approved FY 2023-2024 Annual Report (unanimous)
- Fined CVS Pharmacy No. 5396 $35,000 for controlled substance controls (unanimous)
- Fined Hallandale Pharmacy $53,790 for dispensing products not meeting LA standards (unanimous)
- Approved Stepful Pharmacy Technician Training Program as Board-approved (unanimous)
- Approved revisions to Policy & Procedure Manual for USP compounding standards (unanimous)
- Revoked credential of Destinee Audnell Lyons for alleged diversion of controlled substances (unanimous)
- Authorized PMP reporting waivers for 20 pharmacies (unanimous)
Board of Pharmacy
The Louisiana Board of Pharmacy meets to conduct routine business including approval of minutes, committee reports, and regulatory proposals. The board will consider four regulatory proposals covering automated medication systems, pharmacy technicians, DME permit changes, and prescription transfers. It will also review voluntary consent agreements in disciplinary cases and renew contracts for legal, accounting, and other professional services.
- Regulatory Proposal 2023-C on Automated Medication Systems (Draft #6)
- Regulatory Proposal 2024-A on Pharmacy Technicians (Draft #3)
- Consideration of proposed voluntary consent agreements in violation cases (e.g., Galleria Medical Pharmacy, Jorden Paige Wells)
- Annual renewal of contracts for professional legal services (Celia R. Cangelosi; Shows, Cali & Walsh, LLP)
- Consideration of continuing approval of credentialing examinations (NAPLEX, MPJE, PTCE, ExCPT)
The Board approved four regulatory proposals concerning automated medication systems, pharmacy technician eligibility, DME permit ownership, and prescription transfers. It also issued several disciplinary actions, including license revocations and fines for sterile compounding failures. Additionally, the Board renewed multiple professional service contracts for the 2024-2025 fiscal year.
- Approved Regulatory Proposal 2024-A to expand pharmacy technician candidate eligibility (Unanimous)
- Approved Regulatory Proposal 2024-F regarding electronic prescription transfers (Unanimous)
- Revoked credential of Jorden Paige Wells for OWI and drug possession (Unanimous)
- Fined Galleria Medical Pharmacy $105,000 total for sterile compounding failures (Unanimous)
- Approved $215,000 contract with Bamboo Health, Inc. for prescription monitoring program (Unanimous)
- Approved $125,000 legal services contract with Celia R. Cangelosi (Unanimous)
- Ruled that IV piggybacking is a method of administration, not compounding (Unanimous)
- Rescinded previous Board Orders for Pharmaceutical Specialties, LLC and Michael Marist Bourg (Unanimous)
Board of Pharmacy
The Louisiana Board of Pharmacy will meet to consider proposed voluntary consent agreements in multiple enforcement cases, including those involving CVS Pharmacy, H&W Drug Store, and Hebert's Pharmacy. The board will also review committee recommendations on applications, reciprocity credentials, and regulatory proposals on product integrity, controlled dangerous substance licensing, and open meetings. Public comment will be accepted.
- Consideration of proposed voluntary consent agreements for 9 cases under Violations Committee, including CVS Pharmacy #5607 and H&W Drug Store
- Consideration of proposed voluntary consent agreements and surrenders for 9 cases under General Counsel, including Carepoint Pharmacy and Institutional Pharmacy
- Regulatory Proposal 2024-B on Controlled Dangerous Substance Licensing – Draft #2
- Regulatory Proposal 2024-D on Open Meetings via Electronic Means – Draft #2
- Prescription Monitoring Program (PMP) Quarterly Report and consideration of waiver requests
The Board approved several regulatory and legislative proposals to streamline controlled dangerous substance (CDS) licensing and permit the electronic transfer of CDS prescriptions. The Board also issued multiple fines and reprimands to pharmacies and practitioners for credentialing and audit failures.
- Approved Legislative Proposal 2024-A to permit electronic transfer of CDS prescriptions (unanimous)
- Approved Regulatory Proposal 2024-B to streamline CDS licensing procedures (unanimous)
- Approved $150,000 contract with Tyler Technologies for eLicense system hosting and maintenance (unanimous)
- Approved Albertsons Companies Pharmacy Technician Training Program as Board-approved (unanimous)
- Fined Walker Brother’s Drug $25,000 for allowing a suspended pharmacist to practice (unanimous)
- Fined Ringgold Pharmacy & Wellness $25,000 for allowing a suspended pharmacist to practice (unanimous)
- Fined Hebert’s Pharmacy $15,000 for controlled substance audit shortages (unanimous)
- Approved Regulatory Project 2023-09 Draft #2 regarding product storage (unanimous)